Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared on LinkedIn:
“Patients are voting with their feet when it comes to clinical trial design.
One of the examples I discussed at ESMO2026 was the Phase 3 Krascendo 1 trial. Genentech made the decision to compare investigational divarasib directly with two approved KRAS G12C inhibitors, sotorasib or adagrasib, rather than chemotherapy.
The results presented at ESMO and published in The New England Journal of Medicine demonstrated significantly longer progression-free and overall survival with divarasib.
Developers must consider the conversation an investigator will have with a patient about enrolling in a trial, particularly when that patient already has access to an active therapy. The choice of control arm can have implications for enrollment, the evidence we generate, and ultimately the regulatory and commercial outcome of a program.
As we approach ASH2026, I’m interested in seeing how developers are addressing similar challenges in hematology.
Proceed to the video attached to the post.”
You may also be interested in:
Ahmet Dirican: Exploring Divarasib’s Efficacy Compared With Other KRAS G12C Inhibitors in NSCLC